Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab

Willem H Schreuder; Annet W Coumou; Peter A H W Kessler; Jan de Lange

doi:10.1016/j.joms.2014.02.017

Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab

J Oral Maxillofac Surg. 2014 Jul;72(7):1301-9. doi: 10.1016/j.joms.2014.02.017. Epub 2014 Feb 18.

Authors

Willem H Schreuder¹, Annet W Coumou², Peter A H W Kessler³, Jan de Lange⁴

Affiliations

¹ Oral and Maxillofacial Surgeon, Department of Oral and Maxillofacial Surgery, Academic Medical Center, Academic Center Dentistry Amsterdam, University of Amsterdam, Amsterdam, The Netherlands; Fellow Head and Neck Surgery, Department of Head and Neck Surgery, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: [email protected].
² Attending Physician, Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
³ Professor and Chair of Oral and Maxillofacial Surgery, Department of Cranio-Maxillo-Facial Surgery, University Hospital Maastricht, Maastricht University, Maastricht, The Netherlands.
⁴ Professor and Chair of Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, Academic Medical Center, Academic Center Dentistry Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.

PMID: 24835517
DOI: 10.1016/j.joms.2014.02.017

Abstract

In the search for new pharmacologic therapies for central giant cell granuloma (CGCG), proteins that are essential to osteoclastogenesis are intriguing potential targets. In the present case report, we describe a 25-year-old patient with an aggressive CGCG of the maxilla, who was successfully treated with the antiresorptive agent denosumab, after other pharmacologic treatment had failed to achieve regression or stabilization of the tumor. Denosumab could be a promising alternative to potentially mutilating surgery for CGCG. However, more research is needed before definite conclusions can be drawn about the potential role of this agent in the treatment of CGCG.

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Denosumab
Female
Granuloma, Giant Cell / diagnostic imaging
Granuloma, Giant Cell / drug therapy*
Granuloma, Giant Cell / pathology
Humans
Mouth Neoplasms / diagnostic imaging
Mouth Neoplasms / drug therapy*
Mouth Neoplasms / pathology
RANK Ligand / antagonists & inhibitors
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal, Humanized
RANK Ligand
Denosumab